VIVOS INC. Reports Material Agreement, Officer Changes

Ticker: RDGL · Form: 8-K · Filed: Sep 22, 2025 · CIK: 1449349

Vivos Inc 8-K Filing Summary
FieldDetail
CompanyVivos Inc (RDGL)
Form Type8-K
Filed DateSep 22, 2025
Risk Levelmedium
Pages4
Reading Time5 min
Key Dollar Amounts$192,000, $3,000, $12,000, $30.0 million
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, management-change, corporate-action

TL;DR

VIVOS INC. signed a big deal and shook up management. Keep an eye on this.

AI Summary

VIVOS INC. filed an 8-K on September 22, 2025, reporting on events that occurred on September 15, 2025. The filing indicates a material definitive agreement was entered into, and also covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. Financial statements and exhibits were also filed.

Why It Matters

This filing signals significant corporate activity, including new agreements and potential leadership changes, which could impact the company's strategic direction and operational stability.

Risk Assessment

Risk Level: medium — Changes in directors, officers, and material agreements can introduce uncertainty and potential shifts in company strategy.

Key Players & Entities

  • VIVOS INC. (company) — Registrant
  • September 15, 2025 (date) — Date of earliest event reported
  • September 22, 2025 (date) — Date of Report
  • Delaware (jurisdiction) — State of incorporation
  • 000-53497 (filing_id) — SEC File Number
  • 80-0138937 (tax_id) — IRS Employer Identification No.
  • 1030 N Center Parkway Kennewick , WA 99352 (address) — Principal executive offices

FAQ

What was the nature of the material definitive agreement entered into by VIVOS INC. on September 15, 2025?

The filing indicates a material definitive agreement was entered into, but the specific details of this agreement are not provided in the summary information.

Which directors or officers departed VIVOS INC. on or around September 15, 2025?

The filing states that there was a departure of directors or certain officers, but does not name the individuals involved in the provided summary.

Were there any new appointments or elections for directors or officers at VIVOS INC. on September 15, 2025?

Yes, the filing mentions the election of directors and the appointment of certain officers as events reported for September 15, 2025.

What is the principal executive office address for VIVOS INC.?

The principal executive offices of VIVOS INC. are located at 1030 N Center Parkway Kennewick, WA 99352.

What is the SIC code for VIVOS INC.?

The Standard Industrial Classification (SIC) code for VIVOS INC. is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.

Filing Stats: 1,292 words · 5 min read · ~4 pages · Grade level 12.1 · Accepted 2025-09-19 17:37:17

Key Financial Figures

  • $192,000 — l receive: (i) an annual base salary of $192,000; (ii) a monthly grant of $3,000 in shar
  • $3,000 — ry of $192,000; (ii) a monthly grant of $3,000 in shares common stock of the Company a
  • $12,000 — ) compensation for consulting a rate of $12,000 per month; and (ii) a monthly grant of
  • $30.0 million — capital financing rounds totaling over $30.0 million. Mr. Swanberg has been actively engaged

Filing Documents

02

Item 5.02. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Brad Allan Weeks On September 15, 2025, Vivos Inc. (the " Company ") appointed Brad Allan Weeks as President of the Company, pursuant to an employment agreement entered into between the Company and Mr. Weeks (the " Employment Agreement "). From 2024 to September 15, 2025, Mr. Weeks served as the Company's Business Development Manager for both the IsoPet and RadioGel divisions . Prior to his engagement with the Company, Mr. Weeks served as Quality Assurance and Regulatory Affairs Engineer for Cadwell Industries, Inc. The Employment Agreement provides that Mr. Weeks shall serve as President for a term effective September 1, 2025, ending on December 31, 2027, which term may be extended by written agreement of both parties. Pursuant to the Employment Agreement, Mr. Weeks shall receive: (i) an annual base salary of $192,000; (ii) a monthly grant of $3,000 in shares common stock of the Company at the end of each fiscal quarter based on the closing price of the Company's common stock at the end of such fiscal quarter; and (iii) customary benefits and reimbursement for reasonable out-of-pocket business expenses. The Employment Agreement also provides customary provisions relating to, among other things, clawback rights, confidentiality, non-competition, and non-solicitation. Mr. Weeks is a seasoned leader with extensive experience in the medical device and biotechnology sectors. As President Brad plays a pivotal role in business development, team expansion, and strategic partnerships, contributing to the Company's growth in targeted cancer therapies that deliver radioactive agents directly to tumors while minimizing damage to healthy tissue. Brad has built a distinguished career in healthcare innovation, holding leadership positions at organizations focused on advancing medical techn

SIGNATURES

SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. VIVOS INC. Date: September 18, 2025 By: /s/ Michael K. Korenko Name: Michael K. Korenko Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.